Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Gains from Sales and Divestitures (2016 - 2025)

Tg Therapeutics has reported Gains from Sales and Divestitures over the past 10 years, most recently at $2.3 million for Q4 2025.

  • Quarterly results put Gains from Sales and Divestitures at $2.3 million for Q4 2025, up 0.69% from a year ago — trailing twelve months through Dec 2025 was $2.3 million (up 0.69% YoY), and the annual figure for FY2025 was $2.3 million, up 0.69%.
  • Gains from Sales and Divestitures for Q4 2025 was $2.3 million at Tg Therapeutics, up from $1.8 million in the prior quarter.
  • Over the last five years, Gains from Sales and Divestitures for TGTX hit a ceiling of $6.3 million in Q4 2022 and a floor of $682840.0 in Q1 2021.
  • Median Gains from Sales and Divestitures over the past 5 years was $1.8 million (2025), compared with a mean of $2.0 million.
  • Biggest five-year swings in Gains from Sales and Divestitures: skyrocketed 382.98% in 2022 and later plummeted 60.26% in 2023.
  • Tg Therapeutics' Gains from Sales and Divestitures stood at $1.3 million in 2021, then skyrocketed by 382.98% to $6.3 million in 2022, then plummeted by 60.26% to $2.5 million in 2023, then fell by 9.91% to $2.3 million in 2024, then grew by 0.69% to $2.3 million in 2025.
  • The last three reported values for Gains from Sales and Divestitures were $2.3 million (Q4 2025), $1.8 million (Q3 2025), and $1.6 million (Q2 2025) per Business Quant data.